Maintenance is not an afterthought
GLP-1 and related therapies are often discussed as starts: first prescription, first dose, first milestone. The harder topic is what happens after the initial loss, after a plateau, after a coverage denial, or after a patient wants to reduce or stop therapy.
The questions to plan early
A good maintenance conversation covers target weight, dose strategy, lab and symptom follow-up, nutrition quality, lean-mass protection, medication affordability, pregnancy planning where relevant, and what the clinician recommends if therapy is paused.
- What would make us hold, reduce, or discontinue therapy?
- How will we protect muscle and function while appetite is low?
- What is the plan if insurance coverage changes?
- What data should we review before changing dose?
What the site should track next
Maintenance content should become its own cluster: stopping studies, regain patterns, strength and protein planning, plateaus, dose de-escalation conversations, and long-term safety updates. This is where readers need realistic guidance rather than transformation-story optimism.
Sources and further reading
These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.